

29 Dec 2017 | News

## QUOTED. Dec. 29, 2017. Thomas Burns.

by

Check out what Glaukos Corp. president and CEO Thomas Burns has to say about his firm's minimally invasive glaucoma surgery (MIGS) *iStent inject* device used for treating glaucoma. Glaukos has submitted a pre-market approval application to US FDA for the product.

"This PMA submission marks a significant milestone for Glaukos as we continue to deliver our deep pipeline of novel glaucoma surgical devices and sustained pharmaceuticals. The iStent inject represents the first in a series of five new products we are expecting to introduce over the next five years, culminating in what we believe will be the industry's broadest portfolio of technologies designed to address the full range of glaucoma disease states and progression." – Thomas Burns, president and CEO, Glaukos Corp.

> Find out more: [Glaukos Submits PMA For iStent, Second-Generation MIGS Device For Treating Glaucoma](#)

[Click here](#) for a free trial of *Medtech Insight*